1-5 of 5
Joerg Hoffmann
Close
Sort by
Journal Articles

Pre-Planned Interim Safety Analysis of the Niveau Trial, a Randomized Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma

Lorenz Thurner, MD, Viola Poeschel, MD, Bettina Altmann, PhD, Herve Tilly, MD PhD, Marc Andre, MD, Marie Maerevoet, MD, Thomas Weber, MD, Joerg Hoffmann, MD, Martin Dreyling, MD, Herve Maisonneuve, MD, Andrea Kerkhoff, MD, Steven Le Gouill, MD PhD, Stephan Stilgenbauer, MD, Marita Ziepert, PhD, Roch Houot, MDPhD, Corinne Haioun, MDPhD, Gerhard Held, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32.
https://doi.org/10.1182/blood-2020-139459
Published: 2020
Journal Articles

Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial

Roch Houot, MDPhD, Viola Poeschel, MD, Bettina Altmann, PhD, Thomas Illmer, MD, Marc André, MD, Martin Dreyling, MD, Herve Maisonneuve, MD, Herve Tilly, MD PhD, Stephanie Mayer, MD, Rene-Olivier Casasnovas, MD, Steven Le Gouill, MD PhD, Fritz C. Offner, MD PhD, Guillaume Cartron, MD PhD, Andrea Kerkhoff, MD, Thomas Weber, MD, Joerg Hoffmann, MD, Marita Ziepert, PhD, Wolfram Klapper, MD, Emmanuel Itti, MD PhD, Dirk Hellwig, Laurence De Leval, MD, Andreas Rosenwald, MD, Corinne Haioun, MD PhD, Laurent Dercle, MD, Philippe Gaulard, MD PhD, Gerhard Held, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–34.
https://doi.org/10.1182/blood-2020-136941
Published: 2020
Journal Articles

Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma

Gerhard Held, MD, Corinne Haioun, MD PhD, Roch Houot, MD PhD, Philippe Gaulard, MD PhD, Thierry Molina, Andreas Rosenwald, MD, Marc André, Joerg Hoffmann, MD, Martin Dreyling, MD, Olivier Casasnovas, MD, Herve Maisonneuve, MD, Herve Tilly, MD PhD, Thomas Illmer, Stephanie Mayer, MD, Heinz Kirchen, MD, Paul La Rosée, MD, Markus Loeffler, MD, Marita Ziepert, PhD, Bettina Altmann, PhD, Viola Poeschel, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4085.
https://doi.org/10.1182/blood-2019-129347
Published: 2019
Journal Articles

Hematopoietic Stem Cells Actively Extrude Imatinib-Mesylate Due to High ABCG2-Transporter Activity.

Christian Scharenberg, MD, Michaela Gessner, Joerg Hoffmann, Robert Robey, Andreas Neubauer, MD, Cornelia Brendel, MD
Journal: Blood
Blood (2005) 106 (11): 1372.
https://doi.org/10.1182/blood.V106.11.1372.1372
Published: 2005
Journal Articles

Aldehyde Dehydrogenase Expression in Primitive Human Hematopoietic Progenitor Cells with Side Population Characteristic and in Samples from Patients with Acute Myeloid Leukemia.

Ute Meissauer, Joerg Hoffmann, Christian Scharenberg, MD, Andreas Neubauer, MD, Cornelia Brendel, MD
Journal: Blood
Blood (2005) 106 (11): 4570.
https://doi.org/10.1182/blood.V106.11.4570.4570
Published: 2005